Navigation Links
Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
Date:10/4/2007

DANBURY, Conn., Oct. 4 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Solomon Steiner, Chairman and CEO of Biodel, will present a corporate update at the Natixis Bleichroeder Hidden Gems Conference in New York, NY on October 8th at 10:00 AM ET.

Interested parties may access a link to a live audio webcast of the presentation in the investor relations section of Biodel's website at http://www.biodel.com. A replay of the presentation will be available for 14 days.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.


'/>"/>
SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to ... "Metabolomics Market - Global Industry Analysis, Size, Share, Growth, ... is anticipated to expand at a CAGR of 17.1% ... by 2024. Metabolomics is the extensive study ... biofluids, tissues or organisms. Together, these small molecules and ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... development, skill-building and compliance training platform on mobile devices, today released a new ... Regulatory Requirements for Medical Devices. The course is essential for owners or operators ...
(Date:5/3/2016)... ... 2016 , ... Kerafast Inc., developers of an online ... globe, today announced the availability of a Zika virus antibody from Vanderbilt University. ... prevention measures for the Zika virus, the virus’s geographical distribution continues to widen ...
(Date:5/3/2016)... ... May 03, 2016 , ... According to world renowned ... definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or radiation. ... be made. , New technology has enabled doctors to administer higher doses of ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
(Date:3/1/2016)... March 1, 2016 ... addition of the  "Global Biometric Access ... to their offering. --> ... of the  "Global Biometric Access Control ... their offering. --> Research ...
Breaking Biology News(10 mins):